This is risky business. Only invest what you can afford to lose.
Followers | 0 |
Posts | 1,505 |
Boards Moderated | 0 |
Alias Born | 02/27/2012 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
VYCO new day, new prospects! What will the market hold for us today Gents? ;-D
I agree, a little time and alot more eyes will do it for sure.
Groundswell is coming soon imho
Long play gems are so rare in the penny arena that the market is often slow to grasp what's developing in front of him. Once the organic train has left the station and the chartists can't ignore what's happening, its usually too late to get in on the real screaming deal. Any investor who spent an hour with the fundamental DD here will thank his lucky stars for it in about 6 months
VYCO is the type of organic play where the typical IHUB promo watchers miss out. When the news comes out of ever increasing revenues and market implementation of a medically vital solution to blindess with no competition, it will be too late to grab a nice block at bargain rates. It's the fundamentals here that make it an overlooked gem. As the revenue predictions materialize, the market will recognize and increase the pps in a way that promo based pop and drops can never touch
Great post!
Good things to come here. ;-D
Word just needs to get out and circulate. The organic desire to see again is about as strong a grass roots marketing device as you could ask for.
Old habits dye hard. Its hard to sell "a better mousetrap". What sets VYCO's market offering apart from the gazillion "new and improved widgets" out there, is that there is no competition. There was no previous mousetrap. They have the only FDA approved and medically proved solution to stroke related vision loss, at all. There are 800,000 new stroke victims in the US alone, many who suffer vision loss. The motivation to regain your sight is something that even old school establishment entrenched doctors can hardly hold back forever. Basic physiological motivation. Think Viagara. Once the word truly got out, it would have been difficult to suppress consumer demand...
All indicators point to a continuation of the first quarters 200% revenue increase. The curve should rise steeply in compound fashion throughout 2012. The upside for long term investors is obvious
VYCO fundamentals is so promising for investors who will test out a 6 month hold. 200% revenue increase, $10B industry, only FDA approved treatment for stroke related vision loss, CEO with proven track record for bringing multiple 100 millions into medical device companies, worldwide distibutor network. Everything is in place. 2012 is the year VYCO comes into its own.
VYCO is not the typical IHUB day trader shark fest where you hang onto every fluctuation and nailbite your way to a tiny gain. It s more of a set it and forget it long term hold. It just that the long term fundamentals here are so promising. The upside is just a matter of time for longs
Well, tuesday morning. VYCO closed down a hair yesterday. But it appears there is a fairly dilligent contigent of long term minded investors watching that bid who jump in at every dip
Lets see how we do going into power hour
5,000 shares just bought at ask. Bargain city baby ;-D
Anyway you slice it, nice time to pick up some discounted shares
Not exactly a master of foresight, apparently. They'll wish they'd held on soon enough.
VYCO finally getting a little bit of volume. Filling some cheapies.
Nice Post. Like this: "we believe its current valuation multiple of just 4.2x our 2013 revenue forecast is far too low,
and believe a multiple in the 12x to 15x range is more appropriate."
The clincher for VYCO is having the only patented, FDA approved, scientifically proven treament to actually reverse stroke related blindness/vision loss. Talk about cornering the market. Literally no significant competition on the horizon. NovaVision actually reverses vision loss at a very reasonable price point. I cant remember the last time I saw such an attractive, vital product offering at this level. Simple market logic says there is no way it can stay at this low level IMHO
Lots to look at here. 200% rev increase, big jump in projections for 2012, 3000 medical procedures already performed, distributors in almost all US states, rapidly expanding international presence with roughly a third of revenues coming from abroad and growing...
VYCO has been flying under the radar for quite some time. That won't last much longer IMHO
VYCO has had a behind the scenes accumulation trend the last couple weeks. I think, overall, that will continue this week
Lazy Monday start here for VYCO.
Green close
Sorry bout that bud, for some reason your profile says you do. Are you in here? I'm only checking it out for the first time.
? are you looking at the same l2 I'm looking at?
We've only seen a taste of where this will go. VYCO has been stable, but when the word gets out, there will be no holding it back
Have you gotten your cheapies filled?
Yes the unprecedented nature of such a market offering makes it hard to evaluate. NOONE for the last hundred years thought that stroke related vision loss could be reversed. All in all, though, this is not like a "better mousetrap" product where consumers could simply opt to stay with inferior technology. This is the ONLY FDA approved cure for this condition, and with an affordable pricepoint (a couple thousand) who would actually choose to just stay blind? It really is just a matter of time for this to take off. And when it does, longs will be sitting pretty. ;-D
I agree. Fundamentals here are completely unlike anything at these levels. Once 2012 revs are tallied, and as long as VYCO can execute even a portion of their marketing strategy, the ROI here for longs will be phenomenal. An uptick from the OTCBB would be expected at that point
You can't overstate the strength of being the only FDA approved CURE for stroke related vision loss on the market. Think about that.
200% revenue increase. $10B industry. Patent protected. FDA approved.
VYCO is getting alot of eyes. This is not your typical Ihub shell company penny play. The story here is so solid. This is more of a set it and forget it play. Where you can buy a solid block and let it do what it's gonna do for the next several months.
Don't forget that you have 65% plus insiders holding, and institutional holding also. NOT just a bunch of swing trading IHUBers. CEO Coviello has some serious history building multiplied million revenue med device company's. Lot of confidence on the inside about where VYCO is heading.
"Results: Visual field size increased significantly during training, but a number of cognitive, especially attentional, variables also improved, as did subjective visual function. The size of areas of residual vision was the strongest predictor variable for visual field increase. Demographic and lesion-related variables had little influence on training success."
Vyco's NovaVision is making the blind to see, the scientific DD proves it
"Long and Strong." I'm with you! ;-D
The VYCO story is just legitimately so engrossing. Its hard not to get excited about NovaVision. An FDA, patented CURE for stroke related blindness. What's not to like there? And just the tip of the iceberg...
"VRT is supported by 15 years of research with clinical studies published in more than 30 leading journals including Nature Medicine, Neurology, and The Journal of Cognitive Neuroscience. Results in a retrospective study of 161 patients from 16 US Centers showed that more than 88% of patients experienced a functional improvement such as, improvements in their vision that impact their ability to read, walk, watch TV, and socialize comfortably1 with 75% stating they had better mobility. The average five degree improvement in central vision from VRT can make a significant difference in patients' daily lives, and more than 2,000 patients have been treated."
"Vision Restoration Therapy has been the subject of many clinical studies that have shown it to be effective in about 70 percent of patients who have suffered stroke- or brain injury–related vision loss. A selection of these studies include:
-Computer-Based Training for the Treatment of Partial Blindness
VRT after Brain Damage: Subjective Improvements
-Computer-Based Training of Stimulus Detection Improves Color and Simple Pattern Recognition in the Defective Field of Hemianopic Subjects
-Attentional Cueing Improves Vision Restoration Therapy in Patients with Visual Field Defects"